Anesiva and Transcription Factor sign licensing agreement
Fiscal 2009 Outlook Saxelby concluded, I am very pleased with the progress we’ve made in the first half of fiscal 2009. Landauer’s performance demonstrates the success of our
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).